|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0340 - 0.0380|
|52 Week Range||0.0240 - 0.2150|
|Beta (5Y Monthly)||-17.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for RLFTF
RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced today the appointment of David McCullough as Senior Director and Head of U.S. Market Access, effective August 22 nd . In this newly created position, reporting to Anthony Kim, Senior Vice President and Head of U.S.
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approvalGENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), today announced that the European Commission has granted orphan medicinal product designation in the EU to ACER-001 (sodium phenylbutyrate) for the potential treatment
RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced today promising three-month stability data on a new formulation of RLF-100® (aviptadil).